Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection
The administration of nirmatrelvir/ritonavir and remdesivir lead to the complete resolution of SARS-CoV-2 pneumonia with no side effects in this cohort. The combination of these two antivirals may be a safe option in immunosuppressed population at risk of severe complications and prolonged SARS-CoV-2 infection in order to treat severe clinical presentation and to avoid viral recurrence after chemotherapy.
Authors
- Carlotta Rogati
- Chiara Vismara (ORCID: https://orcid.org/0009-0005-9538-088X)
- A Pazzi
- Massimo Puoti (ORCID: https://orcid.org/0000-0003-3278-7138)
- Roberto Rossotti (ORCID: https://orcid.org/0000-0003-4965-8789)
- Chiara Oltolini (ORCID: https://orcid.org/0000-0002-0088-7890)
- Roberto Cairoli (ORCID: https://orcid.org/0000-0001-6372-2623)
- Marina Deodato (ORCID: https://orcid.org/0000-0003-0010-6107)
- Francesco Peracchi (ORCID: https://orcid.org/0000-0003-3538-3796)
- Nicholas Brian Bana (ORCID: https://orcid.org/0009-0009-6467-3697)
- Davide Motta (ORCID: https://orcid.org/0000-0002-1215-2496)
- Enrico Minetti
- Giovanna Travi (ORCID: https://orcid.org/0000-0002-4206-0066)
- Emanuele Ravano (ORCID: https://orcid.org/0009-0000-3284-8768)
- Valeriana Colombo
- Anna Maria Frustaci (ORCID: https://orcid.org/0000-0003-2587-7901)
- Fulvio Crippa (ORCID: https://orcid.org/0000-0003-0774-1621)
- Marco Merli (ORCID: https://orcid.org/0000-0001-5081-8669)
- Cristina Moioli
- Marta Vecchi (ORCID: https://orcid.org/0000-0002-2917-4587)
- Alessandro Raimondi
- Alice Nava (ORCID: https://orcid.org/0000-0001-8891-623X)
- Diana Fanti
Institutions
- Ospedale Maggiore (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Infectious Disease Reports
- Published
- 2025-02-26
- DOI
- https://doi.org/10.3390/idr17020017
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00